Sanofi has launched a new initiative in its drive to integrate digital technologies ... first task for the accelerator will be to address the needs of patients with atopic dermatitis – a key ...

Sanofi secured amlitelimab as part of its $1.1 billion acquisition of Kymab back in 2021. By 2023, the drug had proven its worth in a phase 2 atopic dermatitis trial, leading the pharma to list ...

The Digital Medicine Society (DiME) is today releasing a new set of open-access resources to advance the use of nocturnal scratch in the treatment of atopic dermatitis (AD). Night-time flare-ups ...

Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the ... have been shown to co-morbidly occur with CSU, such as atopic dermatitis and asthma – providing patients with one ...

an IL-4 and IL-13 inhibitor which Sanofi co-markets with Regeneron Pharmaceuticals. Attovia says ATTO-3712 will offer efficacy and convenient dosing in atopic dermatitis, the drug’s lead ...

Drug is also being tested as a treatment for the skin condition atopic dermatitis, Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with ...

moderate-to-severe atopic dermatitis, eosinophilic esophagitis and prurigo nodularis. Dupixent has become the key driver of the top line for Sanofi as well as Regeneron. In the first quarter of ...

Sanofi and Regeneron’s Dupixent (dupilumab ... Beyond CSU, Dupixent is approved in the US for certain cases of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic ...